Last checked at 15 Oct 2010 11:10
Hikma Pharmaceuticals PLC
LONDON, 15 October 2010 - The Board of Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ: HIK), announces that it has made a block listing application to the Financial Services Authority and the London Stock Exchange for a total of 3,300,000 ordinary shares of 10p each in the capital of the Company to be admitted to the Official List of the UK Listing Authority. It is expected that admission will be granted on 19 October 2010 and trading will commence on 20 October 2010.
The shares, when issued, will be issued fully paid and rank pari passu in all respects with the existing issued ordinary shares of the Company. The shares will be issued pursuant to the vesting of shares under two option plans:
1. 2,600,000 under the Hikma Pharmaceuticals PLC 2004 Stock Option Plan; and
2. 700,000 under the Hikma Pharmaceuticals PLC 2005 Long Term Incentive Plan (together the "Plans").
Participants in the Plans have or will become entitled to these shares following the vesting of the shares.
For further information, please contact:
Henry Knowles, Company Secretary Hikma Pharmaceuticals PLC +44 20 7399 2760
Susan Ringdal, Investor Relations Director
Hikma Pharmaceuticals PLC +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.